Full-Time

Medical Account Specialist 2

Neurology

Updated on 7/21/2026

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$158.9k - $220k/yr

Phoenix, AZ, USA

In Person

Field-based role in Phoenix, AZ area; on-site presence required.

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to Regeneron Pharmaceuticals

Find people who can refer or advise you

Requirements
  • Bachelor’s degree mandatory
  • Minimum 5 years successful experience in Neurology sales and specialty/biologic/REMS products strongly preferred
  • Minimum of (2) years of experience working with key thought leaders or high influence customers in large group practices, academic hospitals, or managed care organizations with a concentration in Neurology
  • Proven success and positive track record of consistent sales performance in complex markets with diverse customer segments operating with a high degree of integrity within compliance guidelines
  • Results oriented with a proven track record of success with product launches
  • Strong account management experience with analytical, problem-solving and planning skills
  • Current account management experience in calling on large Neurology group practices and/or integrated delivery networks
  • Strong understanding of the Neurology therapeutic area and the current Neurology marketplace
Responsibilities
  • Engage Rare Neurology Experts and other key Rare Neurology customers within an assigned geography and deliver clinically focused selling messages to launch product and grow brand share and revenue and to consistently deliver product goals
  • Partner with multiple collaboration stakeholders; Reimbursement and Access Specialists and other stakeholders to proactively address customer needs, market dynamics and trends and develop strategies which support brand and corporate objectives in assigned territory
  • Develops strong working relationships with customers, collaboration colleagues and Internal contacts - Clinics, physicians, nurses, additional important health care providers, key patient advocacy support groups, collaboration teammates, Reimbursement and Access Specialist team, Clinical Nurse Educators, Marketing, National Accounts, Training and Trade
  • Conducts rare neurology-specific market profiling activities to ensure a deep understanding of regional and local health care delivery, influencers and payer systems by the rare neurology account team
  • Deep knowledge of applicable customers and markets (prescribers/HCPs/institutions/ organizations)
  • Strategic account selling and management skills. Develop comprehensive territory/account/customer plans to drive achievement of desired objectives
  • Consistently demonstrates emphasis on the “total account call” insuring that all personnel in the account are educated on commercially available Regeneron products
  • Develop strategy and execute tactics within key accounts in the Rare Neurology therapeutic area to establish, generate and expand market share
  • Proactively identifies business opportunities with assigned accounts and leads appropriate coordination of effort by the Regeneron Rare Neurology account team, e.g. supports contracting pull-through with accounts
  • Gains deep knowledge of each assigned account through internal research and proactive gathering and integration of information from various stakeholders within the account, e.g. business model, relevant business metrics, unique challenges, and strategic goals
Desired Qualifications
  • Launch experience, preferred
  • Master’s degree or additional advanced education/certifications a plus
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lynozyfic achieved near 100% complete response in AL amyloidosis phase 1/2 LINKER-AL2 study.
  • Sanofi profit share surged 42% last quarter, funding pipeline development and offsetting setbacks.
  • $75M Parabulis stake grants strategic access to clinical-stage oncology assets validated by IPO.

What critics are saying

  • AstraZeneca may secure accelerated approval for kappa AL amyloidosis subgroup within 12-18 months.
  • Lynozyfic faces high-risk head-to-head trials with Johnson & Johnson's Darzalex Faspro soon.
  • Intellia's NTLA-2001 gene therapy threatens protein-targeting pipeline with 40-60% probability in 18 months.

What makes Regeneron Pharmaceuticals unique

  • Lynozyfic uses proprietary VelocImmune to create fully human BCMAxCD3 bispecific antibodies.
  • Regeneron secures high-margin cash flow via Sanofi collaboration driven by DUPIXENT sales.
  • Company leverages 35 years of research expertise across cancer, eye, and inflammatory diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Africa SME Journal
Jul 17th, 2026
Gainey McKenna & Egleston announces A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (REGN).

Gainey McKenna & Egleston announces A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (REGN). NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) - Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"). The Complaint alleges that Defendants made materially false and misleading statements regarding the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Regeneron's securities at artificially inflated prices. The Complaint alleges that the full truth finally emerged after-market on May 15, 2026, when Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab... did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." The Complaint also alleges that the investors and analysts again reacted promptly to Regeneron's revelation. The Complaint continues to allege that the price of Regeneron's common stock declined even further from a closing market price of $698.25 per share on May 15, 2026, Regeneron's stock price fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day. Investors who purchased or otherwise acquired shares of Regeneron should contact the Firm prior to the September 14, 2026 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected]. Please visit its website at http://www.gme-law.com for more information about the firm. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

BioTech Health X
Jun 28th, 2026
Top 5 AI-Powered Healthcare Stocks that can make you rich.

Top 5 AI-Powered Healthcare Stocks that can make you rich. * June 28, 2026 Table of contents hide. 5. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ranks fifth among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and this is one of the more important biotechnology names on the list because it combines an established commercial drug portfolio with a continuing push into complex disease areas. Trading at $632.90, with the stock up 2.06%, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is backed by 72 hedge fund holders, showing that institutional investors continue to follow the company despite rising competition in some of its most important markets. For investors searching for healthcare stocks to buy, biotech stocks, pharmaceutical stocks, drug development stocks, immunology stocks, and AI-powered healthcare stocks with long-term upside, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a serious name because it is not simply chasing one product cycle. It has a broader research and development platform, a known commercial portfolio, and a pipeline that continues to attract regulatory attention. Discover more Hygiene & Toiletries HealthCare On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration and the European Medicines Agency accepted regulatory applications for cemdisiran, a treatment candidate for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. That sounds highly technical, but the investment story is straightforward: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trying to expand further into serious immune-mediated diseases where treatment options remain important and where effective therapies can create meaningful commercial value. Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder that can cause muscle weakness and fatigue, making it a disease area where improved treatment convenience and durability can matter a lot for patients and physicians. Pharmaceuticals & Biotech The FDA granted Priority Review for the cemdisiran new drug application, with a target action date set in November 2026 after the use of a priority review voucher. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) also expects a European Commission decision in the second half of 2027. The filings are backed by data from the Phase 3 NIMBLE trial, which evaluated subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic generalized myasthenia gravis. The dosing schedule is a key detail because convenience matters in chronic disease treatment. A medicine that can be administered every 12 weeks may appeal to patients and clinicians if the safety and efficacy profile is compelling enough. For long-term investors, regulatory acceptance itself is not a final approval, but it is a meaningful step that keeps Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)'s pipeline story active. At the same time, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is also dealing with competitive pressure. On the same day, RBC Capital maintained a Sector Perform rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), but the firm described AbbVie's acquisition of Apogee Therapeutics as a "net negative" for the company. RBC Capital argued that the deal adds fuel to a potential next-generation competitor to Dupixent, one of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)'s most important products. The concern is that AbbVie brings commercial expertise and long-standing dermatology market relationships behind Apogee's IL-13 antibody program. In simple market terms, a stronger competitor with a powerful commercial partner can pressure investor sentiment even if the current business remains healthy. The trivia here is that biotechnology investing is often not just about whether a company has good drugs. It is also about timing, regulatory pathways, patent life, competition, payer coverage, physician adoption, and how quickly a rival can build a better or more convenient therapy. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a well-known brand lineup that includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara, which gives the company more depth than many smaller biotech names. Still, the market will continue watching whether Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) can protect its existing franchises while building new growth drivers from its pipeline. Discover more Medical Devices & Equipment Drugs & Medications Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. For investors looking for best healthcare stocks, AI-powered healthcare stocks, biotech stocks to buy, immunology stocks, rare disease treatment stocks, and long-term pharmaceutical stocks, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a high-quality but closely watched name. Its cemdisiran regulatory progress gives investors a fresh pipeline catalyst, while the competitive noise around Dupixent serves as a reminder that even the strongest healthcare companies must keep innovating to defend their market position. Click next to see the following stock...

Gersowitz Libo & Korek, P.C.
Jun 12th, 2026
Manufacturers of Dupixent facing lawsuits over drug outcomes.

Manufacturers of Dupixent facing lawsuits over drug outcomes. * June 12, 2026 Multiple Lawsuits Moving Forward After Plaintiffs Claim that Dupixent May Cause Cutaneous T-Cell Lymphoma MANHATTAN, NEW YORK (June 12, 2026) - Sanofi and Regeneron are facing a variety of lawsuits over claims that Dupixent may cause or potentially accelerate Cutaneous T-Cell Lymphoma. Plaintiffs were using Dupixent to treat their eczema or other inflammatory conditions. Many of those patients were later diagnosed with Cutaneous T-Cell Lymphoma, which is a rare form of non-Hodgkin lymphoma. In June of 2026, many of the lawsuits involving Dupixent were brought together by the District of New Jersey. That litigation remains in its early stages at this time. Despite the lawsuits, the Food and Drug Administration has not yet recalled Dupixent. However, regulators have identified Cutaneous T-Cell Lymphoma as a potential adverse outcome of taking the drug and are weighing whether to take action. Liability for injuries caused by Dupixent. Drug manufacturers have a legal obligation to create products that are reasonably safe. They must study how their products interact with various groups of people and monitor any safety reports related to adverse side effects. When drug manufacturers are aware of a serious risk involving their product, they must warn doctors and patients. With respect to the litigation involving Dupixent, the central question related to liability is whether or not Sanofi and Regeneron failed to warn that their medication could lead to Cutaneous T-Cell Lymphoma. There are a number of other related questions that matter in determining liability. * It matters whether or not Sanofi and Regeneron knew or should have known about any reports that linked Dupixent to Cutaneous T-Cell Lymphoma. * It matters whether or not the manufacturers adequately warned doctors about the dangers of the product. * It matters whether or not patients were kept on Dupixent despite symptoms that may indicate a cancer diagnosis. * It matters whether or not any delayed diagnosis of Cutaneous T-Cell Lymphoma allowed the disease to progress. The litigation involving Dupixent is still relatively new. Sanofi and Regeneron will likely dispute that their medication is causally related to Cutaneous T-Cell Lymphoma. The key issue in drug lawsuits is that of foreseeability. If the manufacturers knew or should have known about the risks with their drug and failed to issue adequate warnings, this could form the basis of a liability claim. In many cases, drug manufacturers may not conduct adequate testing of their product to understand the full range of potential side effects. Steps to take after injuries involving Dupixent. Many people are seriously injured or killed every year due to adverse outcomes from prescription drugs. According to the Centers for Disease Control, "More than 1.5 million people visit emergency departments for ADEs each year in the United States, and almost 500,000 require hospitalization. Older adults (65 years or older) visit emergency departments more than 600,000 times each year, more than twice as often as younger people." Several steps should be taken after any adverse diagnosis related to Dupixent. * Victims should preserve all medical records related to their treatment. * Victims should document their history of taking the medication. * Victims should continue to seek follow-up medical care. * Victims should contact an experienced product liability attorney. It can be difficult to know where to begin after being diagnosed with Cutaneous T-Cell Lymphoma after taking Dupixent. Victims are often left with high medical bills and may need to take extensive periods of time away from work. Sadly, many people never recover. Any person harmed due to the negligent actions of a drug manufacturer should carefully consider their legal options with an experienced attorney. They may be able to seek some measure of accountability or justice through a personal injury claim. Getting legal help for injuries caused by Dupixent. Lawyertime at GLK Law were very concerned to hear about the safety issues associated with Dupixent. The FDA needs to do the right thing and move quickly to protect consumers. Drug manufacturers should be doing everything in their power to ensure that their products are reasonably safe. Have you or a loved one been diagnosed with Cutaneous T-Cell Lymphoma after taking Dupixent? You may have legal recourse. Its team of experienced personal injury attorneys is here for you. Lawyertime is committed to helping victims get the medical and financial assistance that they need to move forward with their lives. Whether you just have legal questions or need any type of support, Lawyertime is here to serve your needs. You can reach out to Lawyertime anytime at (516) 908-9792.

Regeneron Pharmaceuticals
May 19th, 2026
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform  Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately

Endpoints News
Apr 13th, 2026
Regeneron wades into radiopharma through $40M upfront deal with telix.

Regeneron wades into radiopharma through $40M upfront deal with telix. News reporter. Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Think Endpoints Company is worth reading - tell google. Confirm Endpoints as a trusted biopharma news source ENDPOINTS CAREERS TCG stealth clinic-ready newco.